A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma

Cancer

Volumn 116, Issue 15, 2010, Pages 3683-3691

  Weber, Jeffrey S ^a   Samlowski, Wolfram E ^b   Gonzalez, Rene ^c   Ribas, Antoni ^d   Stephenson, Joe ^e   O'Day, Steven ^f   Sato, Takami ^g   Dorr, Robert ^h,i   Grenier, Kathryn ⁱ   Hersh, Evan ^h,i  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Cancer Centers of the Carolinas   (United States)

^f Angeles Clinic and Research Institute   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ AmpliMed Corporation   (United States)

Author keywords

Chemotherapy; Dacarbazine; Imexon; Malignant melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; DACARBAZINE; HEMOGLOBIN; IMEXON; LACTATE DEHYDROGENASE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHILL; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOPENIA; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEARTBURN; HEMOGLOBIN BLOOD LEVEL; HEPATORENAL SYNDROME; HOT FLUSH; HUMAN; INJECTION SITE REACTION; INOPERABLE CANCER; INSOMNIA; LEUKOPENIA; LIMB PAIN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SWEATING; THORAX PAIN; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY FREQUENCY; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HEXANONES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 77955369408     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25119     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 Antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-4745.
3. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007;25:3802-3807.
4. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
5. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase 2 cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase 2 trials. J Clin Oncol. 2008;26:527-534.
6. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase 3 study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;15:158-166.
7. Avril MF, Aamdal S, Grob J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase 3 study. J Clin Oncol. 2004;22:1118-1125.
8. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase 3 study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002;20:125-133.
9. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23:6747-6755.
10. Del Vecchio M, Bajetta E, Vitali M, et al. Multicenter phase 3 randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (SC) interleukin-2 (Il-2) and interferon-alpha-2 n (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol. 2003;22:2849.
11. Iyengar BS, Dorr RT, Remers WA. Chemical basis for the biological activity of imexon & related cyanoaziridines. J Med Chem. 2004;471:218-223.
12. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine containing agent. Biochem Pharmacol. 2000;60:749-758. (Pubitemid 30621659)
13. Pourpack A, Meyers R, Samulitis B, et al. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs. 2006;1710:1179-1184.
14. Scott JA, Dorr RT, Samulitis B, et al. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol. 2007;59:479-757.
15. Hersh EM, Gschwind CR, Taylor CW, et al. Antiproliferative and antitumor activity of the 2-cyanaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst. 1992;84:1238-1244.
16. Salmon SE, Hersh EM. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst. 1992;863:228-230.
17. Saunders PP, Schultz GA. Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis. Biochem Pharmacol. 1970;19:911-919.
18. Cohen SJ, Zalupski M, Modiano M, et al. A phase 1 study of imexon inj. plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity [abstract]. Proc Am Soc Clin Oncol. 2008;26(15 suppl):3589. Abstract 4619.
19. Molder S, Dhillon N, Hong D, et al. A phase 1 study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer [abstract]. Proc Am Soc Clin Oncol. 2008;26(15 suppl):4619. Abstract 3589.
20. Dragovich T, Gordon M, Mendelson D, et al. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol. 2007;253:1779-1784.
21. Simon R. Optimal two-stage designs for phase 2 clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
22. Breithaupt H, Dammann A, Aigner K. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother Pharmacol. 1982;9:103-109.
23. Rajkumar SV, Reid JM, Novotny PJ, et al. A randomized phase 2 and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol. 2000;49:255-261.
24. Samulitis BK, Landowski TH, Dorr RT. Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs. 2009;27:89-98.
25. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of Elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). J Clin Oncol. 2009;27:18s.